News Drug Development

Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson’s Disease

February 1, 2010 |

1 min read

BASEL, Switzerland--(BUSINESS WIRE)--Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.

Clinical research Phase II Europe

MORE ON THIS TOPIC

Relay race. Concept of teamwork. working together of business. Vector illustration

Clinical Research

Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix

December 9, 2025

·

3 min read

·

Annalee Armstrong

Art collage, coins, and arrow up on the red and paper background. Concept of business and financial growth.

Obesity

Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss

December 9, 2025

·

2 min read

·

Tristan Manalac

Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.

Infectious disease

Assembly’s Antivirals Show ‘Striking’ Drop in Lesions, Viral Shedding in Early Genital Herpes Study

December 9, 2025

·

2 min read

·

Tristan Manalac

Hands, tablet and doctor with body hologram, overlay and dna research for medical innovation on app. Medic man, nurse and mobile touchscreen for typing on anatomy study or 3d holographic ux in clinic

Policy

As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation

December 8, 2025

·

3 min read

·

Jennifer Smith-Parker